Kona Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Kona Pharma AG is a privately-held Swiss CDMO with a strong operational history dating back to 1989, now operating as part of the Rhenopharma Group. The company possesses significant manufacturing capabilities across a 14,471 m² facility, with regulatory approvals from Swissmedic, FDA, ANVISA, and TMMDA. Its business model is entirely service-based, focusing on providing end-to-end development and manufacturing solutions for pharmaceutical clients, with no internal drug pipeline.

Small Molecules

Technology Platform

Integrated CDMO infrastructure for solid dosage forms, including development, GMP manufacturing, primary/secondary packaging, and narcotics production. Features a 14,471 m² facility with regulatory approvals from Swissmedic, FDA, ANVISA, and TMMDA.

Opportunities

Leveraging integration into the Rhenopharma Group to offer a complete end-to-end value chain from development to distribution, capturing more client spend.

Its Swiss regulatory pedigree and niche narcotics license provide competitive advantages in serving global pharmaceutical companies seeking high-quality, complex manufacturing.

Risk Factors

Operational risks include reliance on a limited client project portfolio and the constant threat of quality or regulatory compliance failures.

Post-acquisition integration risks with the Rhenopharma Group could disrupt operations or fail to realize promised synergies, hindering growth.

Competitive Landscape

Kona Pharma competes in the crowded global CDMO market, differentiated by its Swiss location and regulatory approvals. Its integration into the Rhenopharma Group pits it against other large, integrated service providers like Lonza, Catalent, and Siegfried, requiring it to compete on both scale and seamless service integration.

More companies in Small Molecule Drugs →More companies in Switzerland →